Eloisa Correa
Family Medicine · Hallandale Beach, FLNPI 1740500149
Payments from drug & device makers
Across 105 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$376
- Novo Nordisk$335
- AstraZeneca$252
- Bayer$232
- Pfizer$191
- Boehringer Ingelheim$190
- plus $954 from 12 others
What the payments were for
- Food & beverage$2,531100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 13 | $376 |
| Novo Nordisk | 7 | $335 |
| AstraZeneca | 16 | $252 |
| Bayer | 7 | $232 |
| Pfizer | 10 | $191 |
| Boehringer Ingelheim | 9 | $190 |
| Boston Scientific | 2 | $154 |
| GSK | 6 | $136 |
| Amarin Pharma, Inc. | 7 | $131 |
| Mallinckrodt Hospital Products Inc. | 5 | $95 |
| Eisai Inc. | 6 | $90 |
| Hologic Sales And Service, LLC | 4 | $89 |
| Insmed, Inc. | 3 | $78 |
| Lilly USA, LLC | 3 | $50 |
| Amgen | 3 | $45 |
| Novartis | 2 | $40 |
| Abbott | 1 | $29 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVANTAGE FIT$136
- Ozempic$125
- RYBELSUS$115
How this compares
$2,531 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $23,359 |
| OzempicSemaglutide | 12 | $11,199 |
| JanuviaSitagliptin Phosphate | 14 | $9,751 |
| Atorvastatin Calcium | 91 | $1,671 |
| Levothyroxine Sodium | 33 | $849 |
| Losartan Potassium | 40 | $738 |
| Metformin Hcl | 50 | $738 |
| Rosuvastatin Calcium | 39 | $706 |
| Amlodipine Besylate | 49 | $663 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 14 | $369 |
| Simvastatin | 18 | $287 |
| Lisinopril | 20 | $269 |
| Gabapentin | 17 | $266 |
| Pantoprazole Sodium | 12 | $259 |
| Metoprolol Succinate | 18 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $190 | $23,35922 claims |
| Novo NordiskOzempic | $335 | $11,19912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Hallandale Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.